E7389-LF

Phase 2Small molecule

Eisai

E7389-LF is one of 39 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Solid TumorPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

E7389-LF

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Active, not recruiting

Solid Tumor

NCT04078295

Phase 1Active, not recruiting

Solid Tumor

NCT03207672

Clinical

Trials by Indication[1]

Solid Tumor2 trials

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Phase 1/2·NCT04078295·125 enrolled

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT03207672·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for E7389-LF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E7389-LF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E7389-LF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eisai

E7389-LF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Solid Tumor2 trials

References

Drug Info

Quick Facts

Related News